FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Garth Powis

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Co-author Network

Publications

TOP 3
Muling Mao; John M Mariadason; Gordon B Mills; Garth Powis; Xi M Tang; Feng Tian; Chun C Tsao; Ignacio I Wistuba; Gideon Bollag; William G Bornman; Michael A Davies; Farshid Dayyani; Jayesh Desai; Gary E Gallick; YN Vashisht Gopal; Zhi-Qin Jiang; Robert Lemos; Scott Kopetz
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Scott Kopetz; Robert Lemos; Garth Powis
The promise of patient-derived xenografts: the best laid plans of mice and men.
Mei Yee Koh; Garth Powis
Passing the baton: the HIF switch.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Garth Powis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Muling Mao; John M Mariadason; Gordon B Mills; Garth Powis; Xi M Tang; Feng Tian; Chun C Tsao; Ignacio I Wistuba; Gideon Bollag; William G Bornman; Michael A Davies; Farshid Dayyani; Jayesh Desai; Gary E Gallick; YN Vashisht Gopal; Zhi-Qin Jiang; Robert Lemos; Scott Kopetz
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(3):657-67.
2012: Scott Kopetz; Robert Lemos; Garth Powis
The promise of patient-derived xenografts: the best laid plans of mice and men.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(19):5160-2.
2012: Mei Yee Koh; Garth Powis
Passing the baton: the HIF switch.
Trends in biochemical sciences 2012;37(9):364-72.
2012: Gerald P Guntle; Bhumasamudram Jagadish; Eugene A. Mash Jr.; Garth Powis; Robert T Dorr; Natarajan Raghunand
Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium.
Translational oncology 2012;5(3):190-9.
2012: Elena V Sheveleva; Geoffrey Bartholomeusz; Terry Landowski; Garth Powis; Betty K Samulitis; Robert T Dorr
Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.
Molecular cancer research : MCR 2012;10(3):392-400.
2012: Nathan T Ihle; Edward S Kim; Jill E Larsen; J Jack Lee; Scott M Lippman; Suyu Liu; John D Minna; Vassiliki A Papadimitrakopoulou; Mena F Abdelmelek; George R Blumenschein; Lauren A Byers; Lu Chen; Kevin R Coombes; Lixia Diao; Roy S Herbst; John V Heymach; Waun K Hong; Pierre Saintigny; Ximing Tang; Anne Tsao; Jing Wang; Ignacio I Wistuba; Shuxing Zhang; Garth Powis
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Journal of the National Cancer Institute 2012;104(3):228-39.
2011: Peter M Glazer; Jennifer Grandis; Thomas Helleday; Richard P Hill; Quynh-Thu Le; Suresh Mohla; Richard Pelroy; Simon N Powell; Garth Powis; Eric J Bernhard; Robert Bristow; J Martin Brown
Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010.
Radiation research 2011;176(3):e0016-21.
2011: Yon Hui Kim; Amanda F Baker; Amy Coon; Garth Powis
Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase.
Cancer chemotherapy and pharmacology 2011;68(2):405-13.
2011: Mei Yee Koh; Robert Lemos; Xiuping Liu; Garth Powis
The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.
Cancer research 2011;71(11):4015-27.
2011: Yong-Wan Kim; Ta Jen Liu; Dimpy Koul; Ningyi Tiao; Abdullah H Feroze; Jing Wang; Garth Powis; W K Alfred Yung
Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.
Neuro-oncology 2011;13(4):367-75.
2011: Ali Md Ahad; Song Zuohe; Lei Du-Cuny; Sylvestor A Moses; Li Li Zhou; Shuxing Zhang; Garth Powis; Emmanuelle J Meuillet; Eugene A. Mash Jr.
Development of sulfonamide AKT PH domain inhibitors.
Bioorganic & medicinal chemistry 2011;19(6):2046-54.
2011: David L Schwartz; James Bankson; Luc Bidaut; Yi He; Ryan Williams; Robert Lemos; Arun Kumar Thitai; Junghwan Oh; Andrei Volgin; Suren Soghomonyan; Hsin-Hsien Yeh; Ryuichi Nishii; Uday Mukhopadhay; Mian Alauddin; Ioseb Mushkudiani; Norihito Kuno; Sunil Krishnan; William Bornman; Stephen Y Lai; Garth Powis; John Hazle; Juri G Gelovani
HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance.
Molecular cancer research : MCR 2011;9(3):259-70.
2011: Ho-Shin Gwak; Takashi Shingu; Vaibhav Chumbalkar; Yeo-Hyeon Hwang; Robert DeJournett; Khatri Latha; Dimpy Koul; W K Alfred Yung; Garth Powis; Nicholas P Farrell; Oliver Bogler
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
International journal of cancer. Journal international du cancer 2011;128(4):787-96.
2011: N T Ihle; Garth Powis; Scott Kopetz
PI-3-Kinase inhibitors in colorectal cancer.
Current cancer drug targets 2011;11(2):190-8.
2011: John K Morrow; Lei Du-Cuny; Lu Chen; Emmanuelle J Meuillet; Eugene A. Mash Jr.; Garth Powis; Shuxing Zhang
Recent development of anticancer therapeutics targeting Akt.
Recent patents on anti-cancer drug discovery 2011;6(1):146-59.
2010: Nancy J Poindexter; Ryan R Williams; Garth Powis; Emily Jen; Abigail S Caudle; Sunil Chada; Elizabeth A Grimm
IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.
Experimental dermatology 2010;19(8):714-22.
2010: David L Schwartz; James Bankson; Robert Lemos; Stephen Y Lai; Arun K Thittai; Yi He; Galen Hostetter; Micheal J Demeure; Daniel Von Hoff; Garth Powis
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.
Molecular cancer therapeutics 2010;9(7):2057-67.
2010: Jörg J Jacoby; Baruch Erez; Maria V Korshunova; Ryan R Williams; Kazuhisa Furutani; Osamu Takahashi; Lynn Kirkpatrick; Scott M Lippman; Garth Powis; Michael S O'Reilly; Roy S Herbst
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(7):940-9.
2010: Dimpy Koul; Ruijun Shen; Yong-Wan Kim; Yasuko Kondo; Yiling Lu; James Bankson; Sabrina M Ronen; D Lynn Kirkpatrick; Garth Powis; W K Alfred Yung
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Neuro-oncology 2010;12(6):559-69.
2010: Nathan T Ihle; Garth Powis
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.
Molecular aspects of medicine 2010;31(2):135-44.
2010: Emmanuelle J Meuillet; Song Zuohe; Robert Lemos; Nathan T Ihle; John Kingston; Ryan Watkins; Sylvestor A Moses; Shuxing Zhang; Lei Du-Cuny; Roy Herbst; Jörg J Jacoby; Li Li Zhou; Ali M Ahad; Eugene A. Mash Jr.; D Lynn Kirkpatrick; Garth Powis
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.
Molecular cancer therapeutics 2010;9(3):706-17.
2010: Nathan T Ihle; Garth Powis
The biological effects of isoform-specific PI3-kinase inhibition.
Current opinion in drug discovery & development 2010;13(1):41-9.
2010: Mei Yee Koh; Taly R Spivak-Kroizman; Garth Powis
HIF-1alpha and cancer therapy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2010;180():15-34.
2009: Mei Yee Koh; Taly R Spivak-Kroizman; Garth Powis
Inhibiting the hypoxia response for cancer therapy: the new kid on the block.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):5945-6.
2009: Lei Du-Cuny; Zuohe Song; Sylvestor Moses; Garth Powis; Eugene A. Mash Jr.; Emmanuelle J Meuillet; Shuxing Zhang
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Bioorganic & medicinal chemistry 2009;17(19):6983-92.
2009: Sylvestor A Moses; M Ahad Ali; Song Zuohe; Lei Du-Cuny; Li Li Zhou; Robert Lemos; Nathan T Ihle; A Geoffrey Skillman; Shuxing Zhang; Eugene A. Mash Jr.; Garth Powis; Emmanuelle J Meuillet
In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.
Cancer research 2009;69(12):5073-81.
2009: Mei Yee Koh; Garth Powis
HAF : the new player in oxygen-independent HIF-1alpha degradation.
Cell cycle (Georgetown, Tex.) 2009;8(9):1359-66.
2009: David L Schwartz; Garth Powis; Arun Thitai-Kumar; Yi He; James Bankson; Ryan Williams; Robert Lemos; Junghwan Oh; Andrei Volgin; Suren Soghomonyan; Ryuichi Nishii; Mian Alauddin; Uday Mukhopadhay; Zhenghong Peng; William G Bornmann; Juri G Gelovani
The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.
Molecular cancer therapeutics 2009;8(4):947-58.
2009: Brian P James; William D Staatz; Sarah T Wilkinson; Emmanuelle Meuillet; Garth Powis
Superoxide dismutase is regulated by LAMMER kinase in Drosophila and human cells.
Free radical biology & medicine 2009;46(6):821-7.
2009: Garth Powis; Nathan T Ihle; W K Alfred Yung
Inhibiting PI-3-K for glioma therapy.
Cell cycle (Georgetown, Tex.) 2009;8(3):335.
2009: Nathan T Ihle; Robert Lemos; David Schwartz; Junghwan Oh; Robert J Halter; Peter Wipf; Lynn Kirkpatrick; Garth Powis
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Molecular cancer therapeutics 2009;8(1):94-100.
2009: Nathan T Ihle; Garth Powis
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
Molecular cancer therapeutics 2009;8(1):1-9.
2009: Nathan T Ihle; Robert Lemos; Peter Wipf; Adly Yacoub; Clint Mitchell; Doris R Siwak; Gordon B Mills; Paul Dent; D Lynn Kirkpatrick; Garth Powis
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Cancer research 2009;69(1):143-50.
2008: Mei Yee Koh; Bryant G Darnay; Garth Powis
Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation.
Molecular and cellular biology 2008;28(23):7081-95.
2008: Mei Yee Koh; Taly R Spivak-Kroizman; Garth Powis
HIF-1 regulation: not so easy come, easy go.
Trends in biochemical sciences 2008;33(11):526-34.
2008: Daruka Mahadevan; Garth Powis; Eugene A. Mash Jr.; Benjamin George; Vijay Gokhale; Shuxing Zhang; Kishore Shakalya; Lei Du-Cuny; Margareta I Berggren; M Ahad Ali; Umasish Jana; Nathan T Ihle; Sylvestor Moses; Chloe Franklin; Satya Narayan; Nikhil Shirahatti; Emmanuelle J Meuillet
Discovery of a novel class of AKT pleckstrin homology domain inhibitors.
Molecular cancer therapeutics 2008;7(9):2621-32.
2008: Amanda F Baker; Mei Y Koh; Ryan R Williams; Brian James; Huamin Wang; Wendy R Tate; Alfred Gallegos; Daniel Von Hoff; Haiyong Han; Garth Powis
Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
Pancreas 2008;36(2):178-86.
2008: Y Yang; Kentaro Iwanaga; Maria Gabriela Raso; Marie Wislez; Amy E Hanna; Eric Wieder; Jeffrey J Molldrem; Ignacio I Wistuba; Garth Powis; Francesco J DeMayo; Carla F. Kim; Jonathan M Kurie
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.
PloS one 2008;3(5):e2220.
2008: Mei Y Koh; Taly Spivak-Kroizman; Sara Venturini; Sarah Welsh; Ryan R Williams; D Lynn Kirkpatrick; Garth Powis
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.
Molecular cancer therapeutics 2008;7(1):90-100.
2007: Amy L Howes; Gary G Chiang; Elizabeth S Lang; Caroline B Ho; Garth Powis; Kristiina Vuori; Robert T Abraham
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.
Molecular cancer therapeutics 2007;6(9):2505-14.
2007: Garth Powis; D Lynn Kirkpatrick
Thioredoxin signaling as a target for cancer therapy.
Current opinion in pharmacology 2007;7(4):392-7.
2007: Amanda F Baker; Terry Landowski; Robert T Dorr; Wendy R Tate; Jaime M C Gard; Breonna E Tavenner; Tomislav Dragovich; Amy Coon; Garth Powis
The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3388-94.
2006: James L Tatum; Gary J Kelloff; Robert J Gillies; Jeffrey M Arbeit; J Martin Brown; K.S. Chao; J Donald Chapman; William Eckelman; Anthony W Fyles; Amato J Giaccia; Richard P Hill; Cameron J Koch; Murali K Cherukuri; Kenneth A Krohn; Jason S Lewis; Ralph P Mason; Giovanni Melillo; Anwar R Padhani; Garth Powis; Joseph G Rajendran; Richard Reba; Simon P Robinson; Gregg L Semenza; Harold M Swartz; Peter Vaupel; David Yang; Barbara Croft; John Hoffman; Guoying Liu; Helen Stone; Daniel Sullivan
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.
International journal of radiation biology 2006;82(10):699-757.
2006: Ryan Williams; Amanda F Baker; Nathan T Ihle; Ashley R Winkler; Lynn Kirkpatrick; Garth Powis
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.
Cancer chemotherapy and pharmacology 2006;58(4):444-50.
2006: Sarah J Welsh; Mei Yee Koh; Garth Powis
The hypoxic inducible stress response as a target for cancer drug discovery.
Seminars in oncology 2006;33(4):486-97.
2006: Adly Yacoub; Margaret A Park; David Hanna; Young Hong; Clint Mitchell; Aditi P Pandya; Hisashi Harada; Garth Powis; Ching-Shih Chen; Constantinos Koumenis; Steven Grant; Paul Dent
OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
Molecular pharmacology 2006;70(2):589-603.
2006: Garth Powis
Achieving personalized cancer medicine: trials and tribulations.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2006;54(5):235-7.
2006: Lars Engman; Michael McNaughton; Malgorzata Gajewska; Sangit Kumar; Anne Birmingham; Garth Powis
Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds.
Anti-cancer drugs 2006;17(5):539-44.
2006: Garth Powis; Nathan T Ihle; D Lynn Kirkpatrick
Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(10):2964-6.
2006: Garth Powis; Peter Wipf; Stephen M Lynch; Anne Birmingham; D Lynn Kirkpatrick
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.
Molecular cancer therapeutics 2006;5(3):630-6.
2006: Amanda F Baker; Tomislav Dragovich; Wendy R Tate; Ramesh K Ramanathan; Denise Roe; Chiu-Hsieh Hsu; D Lynn Kirkpatrick; Garth Powis
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.
The Journal of laboratory and clinical medicine 2006;147(2):83-90.
2005: Peter Wipf; Stephen M Lynch; Garth Powis; Anne Birmingham; Erikah E Englund
Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system.
Organic & biomolecular chemistry 2005;3(21):3880-2.
2005: Bénédicte F Jordan; Kvar Black; Ian F Robey; Matthew Runquist; Garth Powis; Robert J Gillies
Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo.
NMR in biomedicine 2005;18(7):430-9.
2005: Nathan T Ihle; Gillian Paine-Murrieta; Margareta I Berggren; Amanda Baker; Wendy R Tate; Peter Wipf; Robert T Abraham; D Lynn Kirkpatrick; Garth Powis
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Molecular cancer therapeutics 2005;4(9):1349-57.
2005: Amanda F Baker; Tomislav Dragovich; Nathan T Ihle; Ryan Williams; Cecilia Fenoglio-Preiser; Garth Powis
Stability of phosphoprotein as a biological marker of tumor signaling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4338-40.
2005: Bénédicte F Jordan; Matthew Runquist; Natarajan Raghunand; Amanda Baker; Ryan Williams; Lynn Kirkpatrick; Garth Powis; Robert J Gillies
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.
Neoplasia (New York, N.Y.) 2005;7(5):475-85.
2005: Bénédicte F Jordan; Matthew Runquist; Natarajan Raghunand; Robert J Gillies; Wendy R Tate; Garth Powis; Amanda F Baker
The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):529-36.
2004: Debbie Mustacich; Amary Wagner; Ryan Williams; Warner B Bair; Loretta Barbercheck; Steven P Stratton; Achyut K Bhattacharyya; Garth Powis
Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse.
Carcinogenesis 2004;25(10):1983-9.
2004: Emmanuelle J Meuillet; Daruka Mahadevan; Margareta I Berggren; Amy Coon; Garth Powis
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity.
Archives of biochemistry and biophysics 2004;429(2):123-33.
2004: Peter Wipf; Daniel J Minion; Robert J Halter; Margareta I Berggren; Caroline B Ho; Gary G Chiang; Lynn Kirkpatrick; Robert Abraham; Garth Powis
Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.
Organic & biomolecular chemistry 2004;2(13):1911-20.
2004: Nathan T Ihle; Ryan Williams; Sherry Chow; Wade M Chew; Margareta I Berggren; Gillian Paine-Murrieta; Daniel J Minion; Robert J Halter; Peter Wipf; Robert Abraham; Lynn Kirkpatrick; Garth Powis
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.
Molecular cancer therapeutics 2004;3(7):763-72.
2004: Peter Wipf; Stephen M Lynch; Anne Birmingham; Giselle Tamayo; Allan Jiménez; Nefertiti Campos; Garth Powis
Natural product based inhibitors of the thioredoxin-thioredoxin reductase system.
Organic & biomolecular chemistry 2004;2(11):1651-8.
2004: Alan F List; Betty Glinsmann-Gibson; Chad Stadheim; Emmanuelle J Meuillet; William T Bellamy; Garth Powis
Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
Experimental hematology 2004;32(6):526-35.
2004: Garth Powis; Lynn Kirkpatrick
Hypoxia inducible factor-1alpha as a cancer drug target.
Molecular cancer therapeutics 2004;3(5):647-54.
2004: Bennett Kaufman; Orit Scharf; Jeffrey Arbeit; Margaret Ashcroft; J Martin Brown; Richard K Bruick; J Donald Chapman; Sydney M Evans; Amato J Giaccia; Adrian L Harris; Eric Huang; Randall Johnson; William Kaelin; Cameron J Koch; Patrick Maxwell; James Mitchell; Len Neckers; Garth Powis; Joseph Rajendran; Gregg L Semenza; Jonathan Simons; Erik Storkebaum; Michael J Welch; Murray Whitelaw; Giovanni Melillo; S Percy Ivy
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting.
Cancer research 2004;64(9):3350-6.
2004: Sarah J Welsh; Ryan Williams; Lynn Kirkpatrick; Gillian Paine-Murrieta; Garth Powis
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.
Molecular cancer therapeutics 2004;3(3):233-44.
2004: Emmanuelle J Meuillet; Nathan T Ihle; Amanda F Baker; Jaime M C Gard; Chelsea Stamper; Ryan Williams; Amy Coon; Daruka Mahadevan; Benjamin L George; Lynn Kirkpatrick; Garth Powis
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.
Oncology research 2004;14(10):513-27.
2004: Michael McNaughton; Lars Engman; Anne Birmingham; Garth Powis; Ian A Cotgreave
Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth.
Journal of medicinal chemistry 2004;47(1):233-9.
2003: Sarah J Welsh; Garth Powis
Hypoxia inducible factor as a cancer drug target.
Current cancer drug targets 2003;3(6):391-405.
2003: Lars Engman; Nawaf Al-Maharik; Michael McNaughton; Anne Birmingham; Garth Powis
Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells.
Bioorganic & medicinal chemistry 2003;11(23):5091-100.
2003: WALTER WATSON; jan pohl; William R Montfort; Olga Stuchlik; Matthew S Reed; Garth Powis; Dean P Jones
Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif.
The Journal of biological chemistry 2003;278(35):33408-15.
2003: Jennifer Raffel; Achyut K Bhattacharyya; Alfred Gallegos; Haiyan Cui; Janine G Einspahr; David S Alberts; Garth Powis
Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival.
The Journal of laboratory and clinical medicine 2003;142(1):46-51.
2003: Larisa Nonn; Margareta I Berggren; Garth Powis
Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis.
Molecular cancer research : MCR 2003;1(9):682-9.
2003: Bryan Husbeck; David E Stringer; Eugene W Gerner; Garth Powis
Increased thioredoxin-1 inhibits SSAT expression in MCF-7 human breast cancer cells.
Biochemical and biophysical research communications 2003;306(2):469-75.
2003: Emmanuelle J Meuillet; Daruka Mahadevan; Hariprasad Vankayalapati; Margareta I Berggren; Ryan Williams; Amy Coon; Alan P Kozikowski; Garth Powis
Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.
Molecular cancer therapeutics 2003;2(4):389-99.
2003: Sarah J Welsh; Ryan R Williams; Anne Birmingham; David Newman; D Lynn Kirkpatrick; Garth Powis
The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.
Molecular cancer therapeutics 2003;2(3):235-43.
2003: Lars Engman; Nawaf Al-Maharik; Michael McNaughton; Anne Birmingham; Garth Powis
Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants.
Anti-cancer drugs 2003;14(2):153-61.
2003: Larisa Nonn; Ryan R Williams; Robert P Erickson; Garth Powis
The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice.
Molecular and cellular biology 2003;23(3):916-22.
2002: Bryan Husbeck; Garth Powis
The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells.
Carcinogenesis 2002;23(10):1625-30.
2002: Sarah J Welsh; William T Bellamy; Margaret M Briehl; Garth Powis
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
Cancer research 2002;62(17):5089-95.
2001: Peter Wipf; T D Hopkins; JK Jung; S Rodriguez; Anne Birmingham; Eileen C Southwick; John Lazo; Garth Powis
New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead.
Bioorganic & medicinal chemistry letters 2001;11(19):2637-41.
2001: S Kakolyris; A Giatromanolaki; M Koukourakis; Garth Powis; John Souglakos; E Sivridis; Vassilis Georgoulias; K C Gatter; A L Harris
Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):3087-91.
2001: Margareta I Berggren; Bryan Husbeck; Betty K Samulitis; Amanda F Baker; Alfred Gallegos; Garth Powis
Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin.
Archives of biochemistry and biophysics 2001;392(1):103-9.
2001: W Xie; Hairuo Peng; Doeg-Il Kim; M Kunkel; Garth Powis; Leon H Zalkow
Structure-activity relationship of aza-steroids as PI-PLC inhibitors.
Bioorganic & medicinal chemistry 2001;9(5):1073-83.
2001: MM Berggren; Garth Powis
Alternative splicing is associated with decreased expression of the redox proto-oncogene thioredoxin-1 in human cancers.
Archives of biochemistry and biophysics 2001;389(1):144-9.
2001: Suo-Bao Rong; Y Hu; Istvan J Enyedy; Garth Powis; Emmanuelle J Meuillet; X Wu; R Wang; Shaomeng Wang; Alan P Kozikowski
Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides.
Journal of medicinal chemistry 2001;44(6):898-908.
2001: Margaret E Tome; Amanda F Baker; Garth Powis; Claire M Payne; Margaret M Briehl
Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth.
Cancer research 2001;61(6):2766-73.
2001: Hairuo Peng; W Xie; Diane M Otterness; J P Cogswell; R T McConnell; H L Carter; Garth Powis; Robert T Abraham; Leon H Zalkow
Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase.
Journal of medicinal chemistry 2001;44(5):834-48.
2001: Y Hu; Emmanuelle J Meuillet; Margareta I Berggren; Garth Powis; Alan P Kozikowski
3-Deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth.
Bioorganic & medicinal chemistry letters 2001;11(2):173-6.
2001: Bryan Husbeck; Margareta I Berggren; Garth Powis
DNA microarray reveals increased expression of thioredoxin peroxidase in thioredoxin-1 transfected cells and its functional consequences.
Advances in experimental medicine and biology 2001;500():157-68.
2001: Garth Powis; William R Montfort
Properties and biological activities of thioredoxins.
Annual review of biophysics and biomolecular structure 2001;30():421-55.
2001: Garth Powis; William R Montfort
Properties and biological activities of thioredoxins.
Annual review of pharmacology and toxicology 2001;41():261-95.
2000: Lars Engman; T Kandra; Alfred Gallegos; R Williams; Garth Powis
Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells.
Anti-cancer drug design 2000;15(5):323-30.
2000: Y Hu; Lixin Qiao; Shaomeng Wang; Suo-Bao Rong; Emmanuelle J Meuillet; Margareta I Berggren; Alfred Gallegos; Garth Powis; Alan P Kozikowski
3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth.
Journal of medicinal chemistry 2000;43(16):3045-51.
2000: Garth Powis; Debbie Mustacich; Amy Coon
The role of the redox protein thioredoxin in cell growth and cancer.
Free radical biology & medicine 2000;29(3-4):312-22.
2000: A J Freemerman; Garth Powis
A redox-inactive thioredoxin reduces growth and enhances apoptosis in WEHI7.2 cells.
Biochemical and biophysical research communications 2000;274(1):136-41.
2000: Thomas M Grogan; C Fenoglio-Prieser; R Zeheb; William T Bellamy; Yvette M Frutiger; E Vela; G Stemmerman; J Macdonald; Lynne Richter; Alfred Gallegos; Garth Powis
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival.
Human pathology 2000;31(4):475-81.
2000: W Xie; Hairuo Peng; Leon H Zalkow; Y H Li; Cheng Zhu; Garth Powis; M Kunkel
3Beta-hydroxy-6-aza-cholestane and related analogues as phosphatidylinositol specific phospholipase C (PI-PLC) inhibitors with antitumor activity.
Bioorganic & medicinal chemistry 2000;8(4):699-706.
2000: Debbie Mustacich; Garth Powis
Thioredoxin reductase.
The Biochemical journal 2000;346 Pt 1():1-8.
2000: Amanda Baker; B D Santos; Garth Powis
Redox control of caspase-3 activity by thioredoxin and other reduced proteins.
Biochemical and biophysical research communications 2000;268(1):78-81.
2000: Hairuo Peng; W Xie; Doeg-Il Kim; Leon H Zalkow; Garth Powis; Diane M Otterness; Robert T Abraham
Steroidal derived acids as inhibitors of human Cdc25A protein phosphatase.
Bioorganic & medicinal chemistry 2000;8(2):299-306.
2000: L Qiao; Y Hu; Fa-Jun Nan; Garth Powis; Alan P Kozikowski
A versatile approach to PI(3,4)P2, PI(4,5)P2, and PI(3,4,5)P3 from L-(-)-quebrachitol.
Organic letters 2000;2(2):115-7.
1999: D Lynn Kirkpatrick; S Watson; MW Kunkel; S Fletcher; S Ulhaq; Garth Powis
Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.
Anti-cancer drug design 1999;14(5):421-32.
1999: JR Gasdaska; J W Harney; PY Gasdaska; Garth Powis; M J Berry
Regulation of human thioredoxin reductase expression and activity by 3'-untranslated region selenocysteine insertion sequence and mRNA instability elements.
The Journal of biological chemistry 1999;274(36):25379-85.
1999: L C Yeates; Alfred Gallegos; Alan P Kozikowski; Garth Powis
Down regulation of the expression of the p110, p85 and p55 subunits of phosphatidylinositol 3-kinase during colon cancer cell anchorage-independent growth.
Anticancer research 1999;19(5B):4171-6.
1999: A J Freemerman; Alfred Gallegos; Garth Powis
Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells.
Cancer research 1999;59(16):4090-4.
1999: MM Berggren; J F Mangin; J R Gasdaka; Garth Powis
Effect of selenium on rat thioredoxin reductase activity: increase by supranutritional selenium and decrease by selenium deficiency.
Biochemical pharmacology 1999;57(2):187-93.
1999: PY Gasdaska; MM Berggren; M J Berry; Garth Powis
Cloning, sequencing and functional expression of a novel human thioredoxin reductase.
FEBS letters 1999;442(1):105-11.
1999: L E Lemke; Gillian Paine-Murrieta; Charles W Taylor; Garth Powis
Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.
Cancer chemotherapy and pharmacology 1999;44(6):491-7.
1998: Hairuo Peng; Leon H Zalkow; Robert T Abraham; Garth Powis
Novel CDC25A phosphatase inhibitors from pyrolysis of 3-alpha-azido-B-homo-6-oxa-4-cholesten-7-one on silica gel.
Journal of medicinal chemistry 1998;41(24):4677-80.
1998: Lixin Qiao; Fa-Jun Nan; M Kunkel; Alfred Gallegos; Garth Powis; Alan P Kozikowski
3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth.
Journal of medicinal chemistry 1998;41(18):3303-6.
1998: Garth Powis; D Lynn Kirkpatrick; M Angulo; Amanda Baker
Thioredoxin redox control of cell growth and death and the effects of inhibitors.
Chemico-biological interactions 1998;111-112():23-34.
1998: D Lynn Kirkpatrick; M Kuperus; M Dowdeswell; N Potier; Lynda J Donald; MW Kunkel; Margareta I Berggren; M Angulo; Garth Powis
Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides.
Biochemical pharmacology 1998;55(7):987-94.
1998: Hans H Grunicke; Garth Powis
Cell signalling and cancer treatment. AACR special conference in cancer research in collaboration with the British Association for Cancer Research, the German Cancer Society (Section for Experimental Cancer Research), the Austrian Biochemical Society, and the Austrian Cancer Society. 23-28 February 1997, Telfs-Buchen, Austria.
Journal of cancer research and clinical oncology 1998;124(8):462-9.
1997: MW Kunkel; D Lynn Kirkpatrick; John Irwin Johnson; Garth Powis
Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.
Anti-cancer drug design 1997;12(8):659-70.
1997: John F Andersen; D A Sanders; JR Gasdaska; Andrzej Weichsel; Garth Powis; William R Montfort
Human thioredoxin homodimers: regulation by pH, role of aspartate 60, and crystal structure of the aspartate 60 --> asparagine mutant.
Biochemistry 1997;36(46):13979-88.
1997: Amanda Baker; Claire M Payne; Margaret M Briehl; Garth Powis
Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo.
Cancer research 1997;57(22):5162-7.
1997: Lars Engman; Ian A Cotgreave; M Angulo; C W Taylor; Gillian Paine-Murrieta; Garth Powis
Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Anticancer research 1997;17(6D):4599-605.
1997: Alfred Gallegos; Margareta I Berggren; JR Gasdaska; Garth Powis
Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium.
Cancer research 1997;57(21):4965-70.
1997: L C Yeates; Garth Powis
The expression of the molecular chaperone calnexin is decreased in cancer cells grown as colonies compared to monolayer.
Biochemical and biophysical research communications 1997;238(1):66-70.
1997: Margareta I Berggren; Alfred Gallegos; JR Gasdaska; Garth Powis
Cellular thioredoxin reductase activity is regulated by selenium.
Anticancer research 1997;17(5A):3377-80.
1997: Katerina Dvorakova; Robert T Dorr; Alfred Gallegos; TD McClure; Garth Powis
Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice.
Journal of chromatography. B, Biomedical sciences and applications 1997;696(2):275-81.
1997: Garth Powis; Alfred Gallegos; Robert T Abraham; Curtis L Ashendel; Leon H Zalkow; Robert T Dorr; Katerina Dvorakova; Sydney E Salmon; S Harrison; J Worzalla
Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues.
Cancer chemotherapy and pharmacology 1997;41(1):22-8.
1997: D Lynn Kirkpatrick; G Ehrmantraut; S Stettner; MW Kunkel; Garth Powis
Redox active disulfides: the thioredoxin system as a drug target.
Oncology research 1997;9(6-7):351-6.
1997: Garth Powis; JR Gasdaska; PY Gasdaska; Margareta I Berggren; D Lynn Kirkpatrick; Lars Engman; Ian A Cotgreave; M Angulo; Amanda Baker
Selenium and the thioredoxin redox system: effects on cell growth and death.
Oncology research 1997;9(6-7):303-12.
1997: Garth Powis; JR Gasdaska; Amanda Baker
Redox signaling and the control of cell growth and death.
Advances in pharmacology (San Diego, Calif.) 1997;38():329-59.
1996: Alfred Gallegos; JR Gasdaska; Charles W Taylor; Gillian Paine-Murrieta; D Goodman; P Y Gasdaska; Margareta I Berggren; Margaret M Briehl; Garth Powis
Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells.
Cancer research 1996;56(24):5765-70.
1996: JR Gasdaska; D Lynn Kirkpatrick; William R Montfort; M Kuperus; S R Hill; Margareta I Berggren; Garth Powis
Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73-->Ser mutation.
Biochemical pharmacology 1996;52(11):1741-7.
1996: Margareta I Berggren; Alfred Gallegos; JR Gasdaska; P Y Gasdaska; James Warneke; Garth Powis
Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia.
Anticancer research 1996;16(6B):3459-66.
1996: JR Gasdaska; P Y Gasdaska; Alfred Gallegos; Garth Powis
Human thioredoxin reductase gene localization to chromosomal position 12q23-q24.1 and mRNA distribution in human tissue.
Genomics 1996;37(2):257-9.
1996: G Brunner; Leon H Zalkow; E Burgess; Daniel B Rifkin; E L Wilson; E Gruszecka-Kowalik; Garth Powis
Inhibition of glycosylphosphatidylinositol (GPI) phospholipase D by suramin-like compounds.
Anticancer research 1996;16(5A):2513-6.
1996: Andrzej Weichsel; JR Gasdaska; Garth Powis; William R Montfort
Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer.
Structure (London, England : 1993) 1996;4(6):735-51.
1996: A F Baker; Margaret M Briehl; R Dorr; Garth Powis
Decreased antioxidant defence and increased oxidant stress during dexamethasone-induced apoptosis: bcl-2 prevents the loss of antioxidant enzyme activity.
Cell death and differentiation 1996;3(2):207-13.
1996: L Glasser; William S Dalton; R L Fiederlein; P Cook; Garth Powis; W R Vogler
Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid.
Experimental hematology 1996;24(2):253-7.
1995: JR Gasdaska; Margareta I Berggren; Garth Powis
Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1995;6(12):1643-50.
1995: Garth Powis
Anticancer drugs acting against signaling pathways.
Current opinion in oncology 1995;7(6):554-9.
1995: P Y Gasdaska; JR Gasdaska; S Cochran; Garth Powis
Cloning and sequencing of a human thioredoxin reductase.
FEBS letters 1995;373(1):5-9.
1995: Garth Powis; P Y Gasdaska; Alfred Gallegos; K Sherrill; D Goodman
Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs.
Anticancer research 1995;15(4):1141-5.
1995: Richard M Schultz; R L Merriman; Sherri L Andis; R Bonjouklian; G B Grindey; P G Rutherford; Alfred Gallegos; K Massey; Garth Powis
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.
Anticancer research 1995;15(4):1135-9.
1995: P Y Gasdaska; H Fisher; Garth Powis
An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues.
Cancer research 1995;55(12):2542-7.
1995: T Frew; Garth Powis; Margareta I Berggren; Alfred Gallegos; R T Abraham; C L Ashendel; Leon H Zalkow; C Hudson; E Gruszecka-Kowalik; E M Burgess
Novel quinone antiproliferative inhibitors of phosphatidylinositol-3-kinase.
Anti-cancer drug design 1995;10(4):347-59.
1995: Alan P Kozikowski; J J Kiddle; T Frew; Margareta I Berggren; Garth Powis
Synthesis and biology of 1D-3-deoxyphosphatidylinositol: a putative antimetabolite of phosphatidylinositol-3-phosphate and an inhibitor of cancer cell colony formation.
Journal of medicinal chemistry 1995;38(7):1053-6.
1995: J E Oblong; Margareta I Berggren; P Y Gasdaska; S R Hill; Garth Powis
Site-directed mutagenesis of Lys36 in human thioredoxin: the highly conserved residue affects reduction rates and growth stimulation but is not essential for the redox protein's biochemical or biological properties.
Biochemistry 1995;34(10):3319-24.
1995: Garth Powis; S R Hill; T J Frew; K W Sherrill
Inhibitors of phospholipid intracellular signaling as antiproliferative agents.
Medicinal research reviews 1995;15(2):121-38.
1995: M M Briehl; I A Cotgreave; Garth Powis
Downregulation of the antioxidant defence during glucocorticoid-mediated apoptosis.
Cell death and differentiation 1995;2(1):41-6.
1995: Garth Powis; Margareta I Berggren; Alfred Gallegos; T Frew; S Hill; Alan P Kozikowski; R Bonjouklian; Leon H Zalkow; R Abraham; C Ashendel
Advances with phospholipid signalling as a target for anticancer drug development.
Acta biochimica Polonica 1995;42(4):395-403.
1995: Garth Powis; Margaret M Briehl; J Oblong
Redox signalling and the control of cell growth and death.
Pharmacology & therapeutics 1995;68(1):149-73.
1994: Garth Powis; P Workman
Signalling targets for the development of cancer drugs.
Anti-cancer drug design 1994;9(6):555-68.
1994: T Frew; Garth Powis; Margareta I Berggren; R T Abraham; C L Ashendel; Leon H Zalkow; C Hudson; S Qazia; E Gruszecka-Kowalik; R Merriman
A multiwell assay for inhibitors of phosphatidylinositol-3-kinase and the identification of natural product inhibitors.
Anticancer research 1994;14(6B):2425-8.
1994: P Y Gasdaska; J E Oblong; Ian A Cotgreave; Garth Powis
The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors.
Biochimica et biophysica acta 1994;1218(3):292-6.
1994: S R Hill; R Bonjouklian; Garth Powis; R T Abraham; C L Ashendel; Leon H Zalkow
A multisample assay for inhibitors of phosphatidylinositol phospholipase C: identification of naturally occurring peptide inhibitors with antiproliferative activity.
Anti-cancer drug design 1994;9(4):353-61.
1994: Garth Powis; P Workman
Signalling targets for the development of cancer drugs.
Anti-cancer drug design 1994;9(4):263-77.
1994: D E Chapman; S R Michener; Garth Powis
Adenine and pyridine nucleotide concentrations and relationships to 2,6-dinitrotoluene metabolism in cultured rat liver slices.
Toxicology in vitro : an international journal published in association with BIBRA 1994;8(3):343-9.
1994: I Sehgal; S Powers; B Huntley; Garth Powis; M Pittelkow; Nita Maihle
Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(11):4673-7.
1994: Garth Powis; R Bonjouklian; Margareta I Berggren; Alfred Gallegos; R Abraham; C Ashendel; Leon H Zalkow; W F Matter; J Dodge; G Grindey
Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
Cancer research 1994;54(9):2419-23.
1994: Garth Powis
Recent advances in the development of anticancer drugs that act against signalling pathways.
Tumori 1994;80(2):69-87.
1994: J E Oblong; Margareta I Berggren; P Y Gasdaska; Garth Powis
Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin.
The Journal of biological chemistry 1994;269(16):11714-20.
1994: J E Oblong; Margareta I Berggren; Garth Powis
Biochemical, structural, and biological properties of human thioredoxin active site peptides.
FEBS letters 1994;343(1):81-4.
1994: Garth Powis
Signalling pathways as targets for anticancer drug development.
Pharmacology & therapeutics 1994;62(1-2):57-95.
1994: Garth Powis; D Phil
Inhibitors of phosphatidylinositol signalling as antiproliferative agents.
Cancer metastasis reviews 1994;13(1):91-103.
1994: J E Oblong; E L Chantler; A Gallegos; D Lynn Kirkpatrick; T Chen; N Marshall; Garth Powis
Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues.
Cancer chemotherapy and pharmacology 1994;34(5):434-8.
1994: Garth Powis; Alfred Gallegos; R T Abraham; C L Ashendel; Leon H Zalkow; G B Grindey; R Bonjouklian
Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues.
Cancer chemotherapy and pharmacology 1994;34(4):344-50.
1994: G Brunn; Abdul Fauq; S Chow; Alan P Kozikowski; A Gallegos; Garth Powis
Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity.
Cancer chemotherapy and pharmacology 1994;35(1):71-9.
1994: Paul Workman; M D'Incalci; W Bursch; K R Harrap; R E Hawkins; S Neidle; Garth Powis
European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2).
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1148-60.
1994: Garth Powis; D S Alberts
Inhibiting intracellular signalling as a strategy for cancer chemoprevention.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1138-44.
1994: Garth Powis; J E Oblong; P Y Gasdaska; Margareta I Berggren; S R Hill; D Lynn Kirkpatrick
The thioredoxin/thioredoxin reductase redox system and control of cell growth.
Oncology research 1994;6(10-11):539-44.
1993: P Y Gasdaska; Garth Powis; P Hyman; H Fisher
Cigarette smoking is a determinant of DT-diaphorase gene expression in human non-small cell lung carcinoma.
Cancer research 1993;53(22):5458-61.
1993: J E Oblong; Garth Powis
A comment on the absence of calcium regulation of human thioredoxin reductase.
FEBS letters 1993;334(1):1-2.
1993: S C Chow; Garth Powis
Mechanisms of platelet-derived growth factor-induced arachidonic acid release in Swiss 3T3 fibroblasts: the role of a localized increase in free Ca2+ concentration beneath the plasma membrane and the activation of protein kinase C.
Biochimica et biophysica acta 1993;1179(1):81-8.
1993: M I Berggren; Alfred Gallegos; L A Dressler; E J Modest; Garth Powis
Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues.
Cancer research 1993;53(18):4297-302.
1993: J E Oblong; P Y Gasdaska; K Sherrill; Garth Powis
Purification of human thioredoxin reductase: properties and characterization by absorption and circular dichroism spectroscopy.
Biochemistry 1993;32(28):7271-7.
1993: C Gratas; Garth Powis
Inhibition of phospholipase D by agents that inhibit cell growth.
Anticancer research 1993;13(4):1239-44.
1993: D E Chapman; S R Michener; Garth Powis
In vitro metabolism of [(3)H]2,6-dinitrotoluene by human and rat liver.
Toxicology in vitro : an international journal published in association with BIBRA 1993;7(3):213-20.
1993: Margareta I Berggren; L A Burns; R T Abraham; Garth Powis
Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate.
Cancer research 1993;53(8):1862-6.
1993: J J Schlager; B J Hoerl; J Riebow; D P Scott; P Gasdaska; Robert E Scott; Garth Powis
Increased NAD(P)H:(quinone-acceptor)oxidoreductase activity is associated with density-dependent growth inhibition of normal but not transformed cells.
Cancer research 1993;53(6):1338-42.
1993: Paul A Iaizzo; M J Seewald; Garth Powis; R A Van Dyke
The effects of sevoflurane on intracellular Ca2+ regulation in rat hepatocytes.
Toxicology letters 1993;66(1):81-8.
1992: Garth Powis
Drugs active against growth factor and oncogene phosphatidylinositol signalling pathways.
Seminars in cancer biology 1992;3(6):343-50.
1992: D E Chapman; S R Michener; Garth Powis
Metabolism of 2,6-dinitro[3-3H]toluene by human and rat liver microsomal and cytosolic fractions.
Xenobiotica; the fate of foreign compounds in biological systems 1992;22(8):1015-28.
1992: Garth Powis; M J Seewald; C Gratas; D Melder; J Riebow; E J Modest
Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues.
Cancer research 1992;52(10):2835-40.
1992: B L Mau; Garth Powis
Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity.
Biochemical pharmacology 1992;43(7):1621-7.
1992: B L Mau; Garth Powis
Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds.
Biochemical pharmacology 1992;43(7):1613-20.
1992: Garth Powis; M J Seewald; D Melder; M Hoke; C Gratas; T A Christensen; D E Chapman
Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin.
Cancer chemotherapy and pharmacology 1992;31(3):223-8.
1992: Garth Powis; M Seewald; M Hoke
Inhibition of growth factor binding and intracellular Ca2+ signalling by dextran sulfates of different sizes and degrees of sulfation.
Cancer chemotherapy and pharmacology 1992;30(6):483-6.
1991: Garth Powis; Alan P Kozikowski
Growth factor and oncogene signalling pathways as targets for rational anticancer drug development.
Clinical biochemistry 1991;24(5):385-97.
1991: D E Chapman; S R Michener; Garth Powis
Metabolism of the flame retardant plasticizer tris(2-chloroethyl)phosphate by human and rat liver preparations.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1991;17(2):215-24.
1991: Garth Powis
Signalling targets for anticancer drug development.
Trends in pharmacological sciences 1991;12(5):188-94.
1991: Paul A Iaizzo; M J Seewald; R Olsen; Denise J Wedel; D E Chapman; M Berggren; H M Eichinger; Garth Powis
Enhanced mobilization of intracellular Ca2+ induced by halothane in hepatocytes isolated from swine susceptible to malignant hyperthermia.
Anesthesiology 1991;74(3):531-8.
1991: D E Chapman; Garth Powis
Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine.
Cancer chemotherapy and pharmacology 1991;27(4):285-9.
1991: R A Olsen; M J Seewald; D C Melder; M Berggren; Paul A Iaizzo; Garth Powis
Platelet-derived growth factor blocks the increase in intracellular free Ca2+ caused by calcium ionophores and a volatile anesthetic agent in Swiss 3T3 fibroblasts without altering toxicity.
Toxicology letters 1991;55(1):117-25.
1991: Garth Powis; I A Aksoy; D C Melder; S Aksoy; H Eichinger; Abdul Fauq; Alan P Kozikowski
D-3-deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth.
Cancer chemotherapy and pharmacology 1991;29(2):95-104.
1990: Lesley Forrester; John D Hayes; R Millis; D Barnes; Adrian L Harris; J J Schlager; Garth Powis; C Roland Wolf
Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue.
Carcinogenesis 1990;11(12):2163-70.
1990: J P Secrist; I Sehgal; Garth Powis; Robert T Abraham
Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine.
The Journal of biological chemistry 1990;265(33):20394-400.
1990: D E Chapman; T J Moore; S R Michener; Garth Powis
Metabolism and covalent binding of [14C]toluene by human and rat liver microsomal fractions and liver slices.
Drug metabolism and disposition: the biological fate of chemicals 1990;18(6):929-36.
1990: Paul A Iaizzo; R A Olsen; M J Seewald; Garth Powis; A Stier; R A Van Dyke
Transient increases of intracellular Ca2+ induced by volatile anesthetics in rat hepatocytes.
Cell calcium 1990;11(8):515-24.
1990: M J Seewald; R A Olsen; I Sehgal; D C Melder; E J Modest; Garth Powis
Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues.
Cancer research 1990;50(15):4458-63.
1990: Garth Powis; M J Seewald; I Sehgal; Paul A Iaizzo; R A Olsen
Platelet-derived growth factor stimulates non-mitochondrial Ca2+ uptake and inhibits mitogen-induced Ca2+ signaling in Swiss 3T3 fibroblasts.
The Journal of biological chemistry 1990;265(18):10266-73.
1990: Garth Powis; R Olsen; J E Standing; D Kachel; W J Martin
Amiodarone-mediated increase in intracellular free Ca2+ associated with cellular injury to human pulmonary artery endothelial cells.
Toxicology and applied pharmacology 1990;103(1):156-64.
1990: J J Schlager; Garth Powis
Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol.
International journal of cancer. Journal international du cancer 1990;45(3):403-9.
1990: S G Oakes; J J Schlager; K S Santone; Robert T Abraham; Garth Powis
Doxorubicin blocks the increase in intracellular Ca++, part of a second messenger system in N1E-115 murine neuroblastoma cells.
The Journal of pharmacology and experimental therapeutics 1990;252(3):979-83.
1990: A Forbes Howie; Lesley Forrester; M J Glancey; J J Schlager; Garth Powis; Geoffrey J Beckett; John D Hayes; C Roland Wolf
Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues.
Carcinogenesis 1990;11(3):451-8.
1990: R Olsen; D Melder; M Seewald; R Abraham; Garth Powis
Staurosporine inhibition of intracellular free Ca2+ transients in mitogen-stimulated Swiss 3T3 fibroblasts.
Biochemical pharmacology 1990;39(5):968-72.
1990: Paul A Iaizzo; M J Seewald; Garth Powis; R A Van Dyke
The effects of volatile anesthetics on Ca++ mobilization in rat hepatocytes.
Anesthesiology 1990;72(3):504-9.
1990: M J Seewald; R A Olsen; Garth Powis
Suramin blocks intracellular Ca2+ release and growth factor-induced increases in cytoplasmic free Ca2+ concentration.
Cancer letters 1990;49(2):107-13.
1990: B L Mau; Garth Powis
Inhibition of thioredoxin reductase (E.C. 1.6.4.5.) by antitumor quinones.
Free radical research communications 1990;8(4-6):365-72.
1990: J I Brodfuehrer; D E Chapman; T J Wilke; Garth Powis
Comparative studies of the in vitro metabolism and covalent binding of 14C-benzene by liver slices and microsomal fraction of mouse, rat, and human.
Drug metabolism and disposition: the biological fate of chemicals 1990;18(1):20-7.
1989: D J Moore; K P Batts; L L Zalkow; G T Fortune; Garth Powis
Model systems for detecting the hepatic toxicity of pyrrolizidine alkaloids and pyrrolizidine alkaloid N-oxides.
Toxicology and applied pharmacology 1989;101(2):271-84.
1989: P Workman; M I Walton; Garth Powis; J J Schlager
DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs?
British journal of cancer 1989;60(5):800-2; discussion 803.
1989: T J Wilke; W R Jondorf; Garth Powis
Oxidative metabolism of 14C-pyridine by human and rat tissue subcellular fractions.
Xenobiotica; the fate of foreign compounds in biological systems 1989;19(9):1013-22.
1989: Garth Powis; D C Melder; T J Wilke
Human and dog, but not rat, isolated hepatocytes have decreased foreign compound-metabolizing activity compared to liver slices.
Drug metabolism and disposition: the biological fate of chemicals 1989;17(5):526-31.
1989: R Olsen; M Seewald; Garth Powis
Contribution of external and internal Ca2+ to changes in intracellular free Ca2+ produced by mitogens in Swiss 3T3 fibroblasts: the role of dihydropyridine sensitive Ca2+ channels.
Biochemical and biophysical research communications 1989;162(1):448-55.
1989: J M Frazier; C A Tyson; C McCarthy; J J McCormick; D Meyer; Garth Powis; L Ducat
Potential use of human tissues for toxicity research and testing.
Toxicology and applied pharmacology 1989;97(3):387-97.
1989: K L Kooistra; M Rodriguez; Garth Powis
Toxicity of intrathecally administered cytotoxic drugs and their antitumor activity against an intrathecal Walker 256 carcinosarcoma model for meningeal carcinomatosis in the rat.
Cancer research 1989;49(4):977-82.
1989: K S Santone; D C Melder; Garth Powis
Studies of chemical toxicity to fresh and cryopreserved rat hepatocytes.
Toxicology and applied pharmacology 1989;97(2):370-6.
1989: J I Brodfuehrer; T J Wilke; D H Kinder; Garth Powis
Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog.
Cancer chemotherapy and pharmacology 1989;24(5):277-83.
1989: Garth Powis
The use of human liver for foreign compound metabolism and toxicity studies.
Drug metabolism reviews 1989;20(2-4):379-94.
1989: D E Chapman; D J Moore; D C Melder; A Breau; Garth Powis
Isolation, identification and biological activity of a phyllanthoside metabolite produced in vitro by mouse plasma.
Cancer chemotherapy and pharmacology 1989;25(3):184-8.
1989: Garth Powis
Free radical formation by antitumor quinones.
Free radical biology & medicine 1989;6(1):63-101.
1989: M J Seewald; J J Schlager; R A Olsen; D C Melder; Garth Powis
High molecular weight dextran sulfate inhibits intracellular Ca2+ release and decreases growth factor-induced increases in intracellular free Ca2+ in Swiss 3T3 fibroblasts.
Cancer communications 1989;1(3):151-6.
1988: R Olsen; K Santone; D Melder; S G Oakes; R Abraham; Garth Powis
An increase in intracellular free Ca2+ associated with serum-free growth stimulation of Swiss 3T3 fibroblasts by epidermal growth factor in the presence of bradykinin.
The Journal of biological chemistry 1988;263(34):18030-5.
1988: K P Windebank; Robert T Abraham; Garth Powis; R A Olsen; T J Barna; Paul J Leibson
Signal transduction during human natural killer cell activation: inositol phosphate generation and regulation by cyclic AMP.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(11):3951-7.
1988: S G Oakes; P A Iaizzo; E Richelson; Garth Powis
Histamine-induced intracellular free Ca++, inositol phosphates and electrical changes in murine N1E-115 neuroblastoma cells.
The Journal of pharmacology and experimental therapeutics 1988;247(1):114-21.
1988: Leon H Zalkow; J A Glinski; L T Gelbaum; D Moore; D Melder; Garth Powis
Semisynthetic pyrrolizidine alkaloid N-oxide antitumor agents. Esters of heliotridine.
Journal of medicinal chemistry 1988;31(8):1520-6.
1988: Leon H Zalkow; C F Asibal; J A Glinski; S J Bonetti; L T Gelbaum; Donald G Van Derveer; Garth Powis
Macrocyclic pyrrolizidine alkaloids from Senecio anonymus. Separation of a complex alkaloid extract using droplet counter-current chromatography.
Journal of natural products 1988;51(4):690-702.
1988: Garth Powis; I Jardine; R Van Dyke; Richard M Weinshilboum; D Moore; T Wilke; W Rhodes; R Nelson; L Benson; Carol L Szumlanski
Foreign compound metabolism studies with human liver obtained as surgical waste. Relation to donor characteristics and effects of tissue storage.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(4):582-9.
1988: J I Brodfuehrer; Garth Powis
Gas chromatographic assay for the new antitumor agent sulfamic acid diester (NSC 329680) and its stability in buffer, blood and plasma.
Journal of chromatography 1988;427(2):247-55.
1988: J I Brodfüehrer; D J Moore; D C Melder; T J Wilke; Garth Powis
In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation.
Investigational new drugs 1988;6(1):3-9.
1988: P A Southorn; Garth Powis
Free radicals in medicine. II. Involvement in human disease.
Mayo Clinic proceedings. Mayo Clinic 1988;63(4):390-408.
1988: P A Southorn; Garth Powis
Free radicals in medicine. I. Chemical nature and biologic reactions.
Mayo Clinic proceedings. Mayo Clinic 1988;63(4):381-9.
1988: S G Oakes; W J Martin; C A Lisek; Garth Powis
Incomplete hydrolysis of the calcium indicator precursor fura-2 pentaacetoxymethyl ester (fura-2 AM) by cells.
Analytical biochemistry 1988;169(1):159-66.
1988: J I Brodfuehrer; T J Wilke; Garth Powis
Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog.
Cancer chemotherapy and pharmacology 1988;22(2):120-5.
1988: D J Moore; J I Brodfuehrer; T J Wilke; Garth Powis
Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog.
Cancer chemotherapy and pharmacology 1988;21(4):269-73.
1988: J J Schlager; Garth Powis
Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.
Cancer chemotherapy and pharmacology 1988;22(2):126-30.
1987: Garth Powis; D J Moore; T J Wilke; K S Santone
A high-performance liquid chromatography assay for measuring integrated biphenyl metabolism by intact cells: its use with rat liver and human liver and kidney.
Analytical biochemistry 1987;167(1):191-8.
1987: Garth Powis; K S Santone; D C Melder; L Thomas; D J Moore; T J Wilke
Cryopreservation of rat and dog hepatocytes for studies of xenobiotic metabolism and activation.
Drug metabolism and disposition: the biological fate of chemicals 1987;15(6):826-32.
1987: Garth Powis; K L See; K S Santone; D C Melder; E M Hodnett
Quinoneimines as substrates for quinone reductase (NAD(P)H: (quinone-acceptor)oxidoreductase) and the effect of dicumarol on their cytotoxicity.
Biochemical pharmacology 1987;36(15):2473-9.
1987: S G Oakes; K S Santone; Garth Powis
Effect of some anticancer drugs on the surface membrane electrical properties of differentiated murine neuroblastoma cells.
Journal of the National Cancer Institute 1987;79(1):155-61.
1987: H J Long; Garth Powis; A J Schutt; C G Moertel
Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
Cancer treatment reports 1987;71(6):593-8.
1987: Garth Powis; E M Hodnett; K S Santone; K L See; D C Melder
Role of metabolism and oxidation-reduction cycling in the cytotoxicity of antitumor quinoneimines and quinonediimines.
Cancer research 1987;47(9):2363-70.
1987: R A Van Dyke; K L Kooistra; C J Moses; Garth Powis
Effect of inhalation anesthetics on antipyrine pharmacokinetics of mice.
Biochemical pharmacology 1987;36(7):1023-7.
1987: Garth Powis; K L Kooistra
Doxorubicin-induced hair loss in the Angora rabbit: a study of treatments to protect against the hair loss.
Cancer chemotherapy and pharmacology 1987;20(4):291-6.
1987: Garth Powis
Metabolism and reactions of quinoid anticancer agents.
Pharmacology & therapeutics 1987;35(1-2):57-162.
1987: Garth Powis; P Reece; D L Ahmann; J N Ingle
Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.
Cancer chemotherapy and pharmacology 1987;20(3):219-22.
1986: T J Wilke; K L Kooistra; D J Moore; Garth Powis
Gas chromatographic assay for the new antitumor agent pyrazine-2-diazohydroxide (diazohydroxide) and its stability in buffer, blood and plasma.
Journal of chromatography 1986;383(1):77-83.
1986: K S Santone; S G Oakes; Stuart R. Taylor; Garth Powis
Anthracycline-induced inhibition of a calcium action potential in differentiated murine neuroblastoma cells.
Cancer research 1986;46(6):2659-64.
1986: K S Santone; D M Kroschel; Garth Powis
Enhanced formation of ethane and n-pentane by rat hepatocytes in the presence of dimethyl sulfoxide.
Biochemical pharmacology 1986;35(8):1287-92.
1986: Garth Powis; P J Basseches; D M Kroschel; R L Richardson; M J O'Connell; L K Kvols
Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials.
Cancer treatment reports 1986;70(3):359-62.
1986: Garth Powis; R N Harris; P J Basseches; K S Santone
Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse.
Cancer chemotherapy and pharmacology 1986;16(1):43-9.
1986: S Rosenow; K L Kooistra; Garth Powis; R A Van Dyke
Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane.
Cancer chemotherapy and pharmacology 1986;16(1):35-42.
1986: K L Kooistra; M Rodriguez; Garth Powis; T L Yaksh; G J Harty; J F Hilton; E R Laws
Development of experimental models for meningeal neoplasia using intrathecal injection of 9L gliosarcoma and Walker 256 carcinosarcoma in the rat.
Cancer research 1986;46(1):317-23.
1986: P L Appel; M C Alley; M M Lieber; R Shoemaker; Garth Powis
Metabolic stability of experimental chemotherapeutic agents in hepatocyte:tumor cell co-cultures.
Cancer chemotherapy and pharmacology 1986;17(1):47-52.
1986: D J Moore; Garth Powis
Disposition and metabolism of the antitumor glycoside phyllanthoside in mouse and beagle dog.
Cancer chemotherapy and pharmacology 1986;16(3):218-22.
1985: Garth Powis; D M Kroschel; D J Moore
Sensitive reversed-phase high-performance liquid chromatographic assay for the antitumor agent benzisoquinolinedione (Nafidimide) employing direct on-column injection of plasma and urine, and its use for pharmacokinetic studies in a dog.
Journal of chromatography 1985;345(2):402-7.
1985: D J Moore; Garth Powis; R L Richardson; Mark Pittelkow
Topical chemotherapy of intradermal Walker 256 carcinosarcoma with diaziquone and doxorubicin in the rat.
Cancer research 1985;45(11 Pt 1):5466-72.
1985: Garth Powis; D J Moore
High-performance liquid chromatographic assay for the antitumor glycoside phyllanthoside and its stability in plasma of several species.
Journal of chromatography 1985;342(1):129-34.
1985: Garth Powis
Anticancer drug pharmacodynamics.
Cancer chemotherapy and pharmacology 1985;14(3):177-83.
1985: W J Martin; Garth Powis; D L Kachel
Nitrofurantoin-stimulated oxidant production in pulmonary endothelial cells.
The Journal of laboratory and clinical medicine 1985;105(1):23-9.
1984: P J Basseches; Garth Powis
Metabolism and disposition of 3-amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene in the rat.
Cancer research 1984;44(9):3672-8.
1984: Garth Powis; B A Svingen; D C Dahlin; S D Nelson
Enzymatic and non-enzymatic reduction of N-acetyl-p-benzoquinone imine and some properties of the N-acetyl-p-benzosemiquinone imine radical.
Biochemical pharmacology 1984;33(15):2367-70.
1984: P A Reece; J T McCall; Garth Powis; R L Richardson
Sensitive high-performance liquid chromatographic assay for platinum in plasma ultrafiltrate.
Journal of chromatography 1984;306():417-23.
1984: M C Alley; Garth Powis; P L Appel; K L Kooistra; M M Lieber
Activation and inactivation of cancer chemotherapeutic agents by rat hepatocytes cocultured with human tumor cell lines.
Cancer research 1984;44(2):549-56.
1984: R N Harris; P J Basseches; P L Appel; A M Durski; Garth Powis
Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study.
Cancer chemotherapy and pharmacology 1984;12(3):167-72.
1983: Garth Powis; J S Kovach
Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Cancer research 1983;43(2):925-9.
1983: Garth Powis
Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.
Drug metabolism reviews 1983;14(6):1145-63.
1982: P J Basseches; A Durski; Garth Powis
High-performance liquid chromatographic assay of the antineoplastic agent tricyclic nucleoside 5'-phosphate and its disposition in rabbit.
Journal of chromatography 1982;233():227-34.
1982: N Hartman; P J Basseches; Garth Powis
Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.
Cancer chemotherapy and pharmacology 1982;10(1):11-5.
1982: Garth Powis
Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.
Cancer treatment reviews 1982;9(2):85-124.
1982: R T Eagan; M M Ames; Garth Powis; J S Kovach
Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol.
Cancer treatment reports 1982;66(2):283-7.
1982: Garth Powis; B A Svingen; C Degraw
Iron-EDTA stimulated reduction of indicine N-oxide by the hepatic microsomal fraction, isolated hepatocytes, and the intact rat.
Biochemical pharmacology 1982;31(3):293-9.
1982: M J O'Connell; Garth Powis; J Rubin; C G Moertel
Pilot study of PALA and 5-FU in patients with advanced cancer.
Cancer treatment reports 1982;66(1):77-80.
1981: Garth Powis
Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride.
Journal of chromatography 1981;226(2):514-20.
1981: J S Kovach; R T Eagan; Garth Powis; J Rubin; Edward T. Creagan; C G Moertel
Phase I and pharmacokinetic studies of DON.
Cancer treatment reports 1981;65(11-12):1031-6.
1981: B A Svingen; Garth Powis; P L Appel; M Scott
Protection against adriamycin-induced skin necrosis in the rat by dimethyl sulfoxide and alpha-tocopherol.
Cancer research 1981;41(9 Pt 1):3395-9.
1981: Garth Powis; B A Svingen; P Appel
Quinone-stimulated superoxide formation by subcellular fractions, isolated hepatocytes, and other cells.
Molecular pharmacology 1981;20(2):387-94.
1981: B A Svingen; Garth Powis
Pulse radiolysis studies of antitumor quinones: radical lifetimes, reactivity with oxygen, and one-electron reduction potentials.
Archives of biochemistry and biophysics 1981;209(1):119-26.
1981: B A Svingen; Garth Powis; P L Appel; M Scott
Protection by alpha-tocopherol and dimethylsulfoxide (DMSO) against adriamycin induced skin ulcers in the rat.
Research communications in chemical pathology and pharmacology 1981;32(1):189-92.
1981: Garth Powis; J S Kovach
Binding of copper and zinc by the antitumour agent L-alanosine.
Biochemical pharmacology 1981;30(7):771-6.
1981: Louis Letendre; W A Smithson; G S Gilchrist; E O Burgert; C H Hoagland; M M Ames; Garth Powis; J S Kovach
Activity of indicine N-oxide in refractory acute leukemia.
Cancer 1981;47(3):437-41.
1981: M M Lieber; M M Ames; Garth Powis; J S Kovach
Anticancer drug testing in vitro: use of an activating system with the human tumor stem cell assay.
Life sciences 1981;28(3):287-93.
1981: Garth Powis; M M Ames; J S Kovach
Dose-dependent pharmacokinetics and cancer chemotherapy.
Cancer chemotherapy and pharmacology 1981;6(1):1-9.
1981: Garth Powis; B A Svingen; P Appel
Factors affecting the intracellular generation of free radicals from quinones.
Advances in experimental medicine and biology 1981;136 Pt A():349-58.
1980: Garth Powis; P L Appel
Relationship of the single-electron reduction potential of quinones to their reduction by flavoproteins.
Biochemical pharmacology 1980;29(19):2567-72.
1980: Garth Powis; C L DeGraw
N-Oxide reduction by hemoglobin, cytochrome C and ferrous ions.
Research communications in chemical pathology and pharmacology 1980;30(1):143-50.
1980: E D Moore; Garth Powis
Plasma and tissue concentrations of hycanthone in the mouse determined by reversed-phase high-performance liquid chromatography.
Journal of chromatography 1980;183(3):372-7.
1980: Garth Powis; L Wincentsen
Pyridine nucleotide cofactor requirements of indicine N-oxide reduction by hepatic microsomal cytochrome P-450.
Biochemical pharmacology 1980;29(3):347-51.
1980: Garth Powis; M M Ames
Determination of 6-diazo-5-oxo-L-norleucine in plasma and urine by reversed-phase high-performance liquid chromatography of the dansyl derivative.
Journal of chromatography 1980;181(1):95-9.
1979: M M Ames; Garth Powis; J S Kovach; R T Eagan
Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans.
Cancer research 1979;39(12):5016-21.
1979: J S Kovach; M M Ames; Garth Powis; C G Moertel; Richard G Hahn; Edward T. Creagan
Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans.
Cancer research 1979;39(11):4540-4.
1979: Garth Powis; M M Ames; J S Kovach
Metabolic conversion of indicine N-oxide to indicine in rabbits and humans.
Cancer research 1979;39(9):3564-70.
1979: Garth Powis; M M Ames; J S Kovach
Relationship of the reductive metabolism of indicine N-oxide to its antitumor activity.
Research communications in chemical pathology and pharmacology 1979;24(3):559-69.
1979: M M Ames; Garth Powis
Determination of pentamethylmelamine and hexamethylmelamine in plasma and urine by nitrogen-phosphorus gas-liquid chromatography.
Journal of chromatography 1979;174(1):245-9.
1979: J B Schenkman; I Jansson; Garth Powis; H Kappus
Active oxygen in liver microsomes: mechanism of epinephrine oxidation.
Molecular pharmacology 1979;15(2):428-38.
1979: Garth Powis; M M Ames
Determination of L-alanosine in plasma and urine by reversed-phase high-performance liquid chromatography of the Dns derivative.
Journal of chromatography 1979;170(1):195-201.
1979: M M Ames; Garth Powis; P Kuehn
Determination of pyrazoloimidazole in plasma and urine by gas-liquid chromatography using nitrogen-phosphorus detection.
Journal of chromatography 1979;169():412-5.
1979: Garth Powis; I Jansson
Stoichiometry of the mixed function oxidase.
Pharmacology & therapeutics 1979;7(2):297-311.
1979: Garth Powis
Hepatic microsomal metabolism of epinephrine and adrenochrome by superoxide-dependent and -independent pathways.
Biochemical pharmacology 1979;28(1):83-9.
1978: M M Ames; Garth Powis
Determination of indicine N-oxide and indicine in plasma and urine by electron-capture gas-liquid chromatography.
Journal of chromatography 1978;166(2):519-26.
1978: Garth Powis; D H Snow
The effects of exercise and adrenaline infusion upon the blood levels of propranolol and antipyrine in the horse.
The Journal of pharmacology and experimental therapeutics 1978;205(3):725-31.
1978: M A Khoyi; A Pousti; Garth Powis; M R Zarrindast
Tachyphylaxis to ethacrynic acid in the isolated atrium of guinea-pig and its relation to noradrenaline stores.
British journal of pharmacology 1978;63(1):191-6.
1977: Garth Powis; Jeff Cummings; E Morgan
The effect of adrenalectomy upon the absorption, distribution and metabolism of ethanol in the rat.
Life sciences 1977;21(7):1033-6.
1977: Leslie H Blumgart; A M Harper; D P Leiberman; R T Mathie; Garth Powis
Liver blood flow measurements with 85kripton clearance by portal venous and hepatic arterial routes of injection [proceedings].
British journal of pharmacology 1977;60(2):278P.
1977: S Mabrey; Garth Powis; J B Schenkman; T R Tritton
Calorimetric study of microsomal membrane.
The Journal of biological chemistry 1977;252(9):2929-33.
1977: Garth Powis
Drug clearance in the rabbit twenty-four hours after an intoxicating dose of ethanol [proceedings].
British journal of pharmacology 1977;59(3):490P-491P.
1977: Garth Powis; I Jansson; J B Schenkman
The effects of albumin upon the spectral changes and metabolism by the hepatic microsomal fraction.
Archives of biochemistry and biophysics 1977;179(1):34-42.
1977: Garth Powis; L Lyon; D McKillop
NADH synergism of microsomal aniline metabolism in the presence of enhancing agents.
Biochemical pharmacology 1977;26(2):137-41.
1976: Garth Powis; L Grant
The effect of inhibitors of alcohol metabolism upon the changes in the hepatic microsomal metabolism of foreign compounds produced by the acute administration of some alcohols to the rat.
Biochemical pharmacology 1976;25(19):2197-201.
1976: D McKillop; Garth Powis
The metabolism and binding of catecholamines by the hepatic microsomal mixed-function oxidase of the rat.
The Biochemical journal 1976;158(1):135-40.
1976: L Grant; Garth Powis
Proceedings: The effect of inhibitors of alcohol metabolism on the changes in the hepatic microsomal metabolism of foreign compounds produced by a single dose of ethanol in the rat.
British journal of pharmacology 1976;56(3):376P-377P.
1976: Garth Powis; A H Drummond; D E Macintyre; W R Jondorf
Development of liver microsomal oxidations in the chick.
Xenobiotica; the fate of foreign compounds in biological systems 1976;6(2):69-81.
1976: D McKillop; Garth Powis
The metabolism and binding of catecholamines by the hepatic microsomal fraction of the rat.
Biochemical Society transactions 1976;4(1):145-7.
1975: Garth Powis
The binding of catecholamines to the serum proteins of the rat and the domestic fowl.
Comparative biochemistry and physiology. C: Comparative pharmacology 1975;52(2):85-90.
1975: Garth Powis; A R Boobis
Effect of washing the hepatic microsomal fraction in sucrose solutions and in sucrose solution containing EDTA upon the metabolism of foreign compounds.
Biochemical pharmacology 1975;24(19):1771-6.
1975: Garth Powis
Effect of a single oral dose of methanol, ethanol and propan-2-ol on the hepatic microsomal metabolism of foreign compounds in the rat.
The Biochemical journal 1975;148(2):269-77.
1975: Garth Powis
The binding of catecholamines to human serum proteins.
Biochemical pharmacology 1975;24(6):707-12.
1975: D McKillop; Garth Powis
The effect of a single dose of ethanol on the hepatic microsomal metabolism of foreign compounds in the rat.
British journal of pharmacology 1975;53(3):442P.
1975: A R Boobis; Garth Powis
The metabolism and disposition of aniline in the isolated blood-perfused liver of the rat.
Drug metabolism and disposition: the biological fate of chemicals 1975;3(2):63-8.
1975: Garth Powis; A R Boobis
The effect of pretreating rats with 3-methylcholanthrene upon the enhancement of microsomal aniline hydroxylation by acetone and other agents.
Biochemical pharmacology 1975;24(3):424-6.
1974: A R Boobis; Garth Powis
The effects of catecholamines upon the metabolism of foreign compounds and upon the distribution of perfusate in the isolated liver of the rat.
Biochemical pharmacology 1974;23(24):3377-84.
1974: Garth Powis
Effect of serum albumin upon the response of the rat isolated superfused anococcygeus muscle to catecholamines and to nerve stimulation.
The Journal of pharmacy and pharmacology 1974;26(5):344-7.
1974: A G Blakeley; Garth Powis; R J Summers
An uptake mechanism for L-noradrenaline in the cat spleen, associated with the nerves but distinct from uptake.
The Journal of physiology 1974;238(1):193-206.
1974: H Clark; Garth Powis
Effect of acetone administered in vivo upon hepatic microsomal drug metabolizing activity in the rat.
Biochemical pharmacology 1974;23(5):1015-9.
1974: Garth Powis
A study of the interaction of tetracycline with human serum lipoproteins and albumin.
The Journal of pharmacy and pharmacology 1974;26(2):113-8.
1973: A G Blakeley; Garth Powis; R J Summers
Proceedings: Uptake of (L)-noradrenaline in the isolated cat heart perfused with blood containing desmethylimipramine (DMI) and 17-beta-oestradiol (17beta0).
The Journal of physiology 1973;234(2):108P-109P.
1973: Garth Powis
Binding of catecholamines to connective tissue and the effect upon the responses of blood vessels to noradrenaline and to nerve stimulation.
The Journal of physiology 1973;234(1):145-62.
1973: A Boobis; Garth Powis
Proceedings: The isolated perfused rat liver in the study of the metabolism of foreign compounds.
British journal of pharmacology 1973;49(1):185P-186P.
1973: A G Blakeley; Garth Powis; R J Summers
The effects of pargyline on overflow of transmitter and uptake of noradrenaline in the cat spleen.
British journal of pharmacology 1973;47(4):719-28.
1973: Garth Powis
The accumulation and metabolism of (-)-noradrenaline by cells in culture.
British journal of pharmacology 1973;47(3):568-75.
1973: A G Blakeley; Garth Powis; R J Summers
Some characteristics of the uptake process in the isolated blood perfused cat spleen resistant to desmethylimipramine and 17- -oestradiol.
British journal of pharmacology 1973;47(3):634P-635P.
1973: W R Jondorf; D E MacIntyre; Garth Powis
Induction of liver microsomal drug metabolism in newly-hatched chicks.
British journal of pharmacology 1973;47(3):624P-625P.
1973: A G Blakeley; Garth Powis; R J Summers
An uptake process for L-noradrenaline resistant to desmethylimipramine (DMI) and 17 -estradiol in the cat spleen.
The Journal of physiology 1973;229(1):31P-32P.
1971: A G Blakeley; Garth Powis; R J Summers
Effect of the monoamine oxidase inhibitor pargyline on the uptake of labelled noradrenaline by the cat's spleen.
British journal of pharmacology 1971;43(2):451P-452P.
1971: D S Parsons; Garth Powis
Some properties of a preparation of rat colon perfused in vitro through the vascular bed.
The Journal of physiology 1971;217(3):641-63.
1970: Garth Powis
Perfusion of rat's liver with blood: transmitter overflows and gluconeogenesis.
Proceedings of the Royal Society of London. Series B, Containing papers of a Biological character. Royal Society (Great Britain) 1970;174(37):503-15.